Protalix Biotherapeutics Inc Stock price TEL AVIV STOCK EXCHANGE
Equities
US74365A1016
Biotechnology & Medical Research
Sales 2024 * | 74.06M 27.09B | Sales 2025 * | 127M 46.59B | Capitalization | 92.05M 33.67B |
---|---|---|---|---|---|
Net income 2024 * | 17M 6.22B | Net income 2025 * | 70M 25.61B | EV / Sales 2024 * | 1.24 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.72 x |
P/E ratio 2024 * |
6
x | P/E ratio 2025 * |
1.56
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.23% |
Latest transcript on Protalix Biotherapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 57 | 19-06-29 |
Eyal Rubin
DFI | Director of Finance/CFO | 48 | 19-07-21 |
Yael Hayon
CTO | Chief Tech/Sci/R&D Officer | 41 | 20-07-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 67 | 19-11-30 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 19-11-30 |
Aharon Schwartz
BRD | Director/Board Member | 80 | 14-10-31 |
1st Jan change | Capi. | |
---|---|---|
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |